A Phase 3 interventional study of HBS-301 and Placebo in EDS, Cataplexy and Fatigue, sponsored by Harmony Biosciences Management, Inc.. Recruiting at 64 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Harmony Biosciences Management, Inc. (part of Harmony Biosciences Holdings, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Cataplexy with a site in United States — 4 open to participants now, 4 under way, 4 of them phase 3. Cataplexy · United States.
Among the 16 studies in Cataplexy with a site in United States, this one is the 4th largest by planned enrollment, is one of 4 that started in 2026, is one of 10 in phase 3, and was the 16th registered.
31 studies on the registry are indexed under Cataplexy; 5 are open to participants now.
Browse Cataplexy studies →4 of the 16 studies in Cataplexy with a site in United States are open now. Recruiting first, the newest first:
Suven Life Sciences Limited · Sites in United States
Ages 18+
Centessa Pharmaceuticals (UK) Limited · Sites in United States
Ages 18–70
Alkermes, Inc. · Sites in United States, Australia, Belgium and 7 more countries
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Cataplexy studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 11
First in 2000; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 258 is above the median of 117 across 27 interventional studies indexed under Cataplexy.
Median enrollment 195 across the 16 interventional studies. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 16 have an industry lead sponsor. The 10 most frequent:
This study is registered under Harmony Biosciences Management, Inc., one of the names counted as Harmony Biosciences Holdings, Inc.. Under that name alone:
Harmony Biosciences Management, Inc. is the lead sponsor of 16 studies on the registry; 6 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.
Harmony Biosciences Holdings, Inc. has 1 study filed under Cataplexy — fewer than ten, so there is no comparison to draw.
4 of the studies in Cataplexy with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07455383Phase 3Alkermes, Inc.A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 | 2027-05 |
| NCT07598708Phase 3Centessa Pharmaceuticals (UK) LimitedA Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence | 2027-09-30 |
| NCT07675135Phase 3Harmony Biosciences Management, Inc.A Phase 3 Efficacy and Safety Study of HBS-301 in Participants With Narcolepsy | 2027-10 |
| NCT07540364Phase 3Suven Life Sciences LimitedA Phase 3 Study to Evaluate the Efficacy and Safety of Samelisant in Patients With Narcolepsy (AWAKE) | 2027-11-19 |
Add all 4 to your calendar (.ics) → With an account.
Among the 16 studies in Cataplexy with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-301 in treating excessive daytime sleepiness (EDS), cataplexy, sleepiness/wakefulness, and fatigue in adult participants (ages ≥18 years) with narcolepsy.
This is a Phase 3, multicenter, randomized, double-blind, parallel-group, placebo-controlled clinical study to assess the efficacy and safety of HBS-301 in treating EDS, cataplexy, sleepiness/wakefulness, and fatigue in adult participants (ages ≥18 years) with narcolepsy.
Approximately 258 participants are planned for randomization into the study. The study will consist of a Screening/Baseline Period (up to 28 days), a Double-blind Treatment Period (8 weeks), an optional Open-label Extension Period (1 year), and 30 days of safety follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HBS-301 tablets administered once daily in the morning upon wakening
Drug: HBS-301
Matching placebo tablets administered once daily in the morning upon wakening
Other: Placebo
HBS-301 tablets administered once daily in the morning upon wakening
Drug: HBS-301
HBS-301 tablet
Also known as: pitolisant delayed-release
Placebo tablet
Change in severity of EDS as measured by the Epworth Sleepiness Scale (ESS)
The ESS is an 8-item, 4-point rating scale.
Time frame: Baseline to end of Double-Blind Treatment Period (8 weeks)
Change in Weekly Rate of Cataplexy (WRC) in participants with an average WRC of ≥3 over 2 consecutive weeks at Screening
The WRC is the average number of cataplexy attacks per week.
Time frame: End of the Double-Blind Treatment Period (8 weeks)
Change in sleepiness/wakefulness measured by the Maintenance of Wakefulness Test (MWT)
The MWT consists of a series of 20-minute to 40-minute trials spaced 2 hours apart and is used to measure an individual's ability to stay awake.
Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)
Change in fatigue as measured by the Patient-Reported Outcomes Measurement Information System Fatigue Short Form 7a (PROMIS-Fatigue-SF-7a)
The PROMIS-Fatigue-SF-7a is a 7-question, 5-point scale used to assess fatigue.
Time frame: Baseline to end of Double-Blind Treatment Period (8 weeks)
Change in severity of EDS as measured by the ESS
The ESS is an 8-item, 4-point rating scale.
Time frame: Baseline through Week 1 and through Week 2 of Titration Period (1 week and 2 weeks)
Onset of efficacy of HBS-301 compared with placebo in treating cataplexy measured by WRC in participants with an average WRC of ≥3 over 2 consecutive weeks during Screening
The WRC is the average number of cataplexy attacks per week.
Time frame: Baseline through Week 1 and Week 2 of the Titration Period (1 week and 2 weeks)
Change in severity of EDS as measured by the Clinical Global Impression of Change (EDS)
The Clinical Global Impression of Change (EDS) is a 7-point scale used to measure the improvement or worsening of the participant's EDS relative to a baseline.
Time frame: Baseline to end of Double-blind Treatment Period (8 weeks)
Change in severity of EDS as measured by the Patient Global Impression of Severity (EDS)
The Patient Global Impression of Severity (EDS) is a participant-reported assessment that gauges the severity of a participant's EDS symptoms.
Time frame: Time Frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)
Improvement in the severity of EDS as measured by the Patient Global Impression of Change (EDS)
The Patient Global Impression of Change (EDS) is a participant-reported outcome used to evaluate the effectiveness of a treatment on their EDS symptoms.
Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)
Change in severity of cataplexy as measured by the Clinical Global Impression of Severity (Cataplexy) in participants with an average WRC of ≥3 over 2 consecutive weeks during Screening
The Clinical Global Impression of Severity (Cataplexy) is a 3-item observer-rated scale used to track cataplexy symptom changes.
Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)
Change in severity of cataplexy as measured by the Patient Global Impression of Severity (Cataplexy) in participants with an average WRC of ≥3 over 2 consecutive weeks during Screening
The Patient Global Impression of Severity (Cataplexy) is a participant-reported assessment that gauges the severity of cataplexy symptoms.
Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)
Improvement in severity of cataplexy as measured by the Patient Global Impression of Change (Cataplexy) in participants with an average WRC of ≥3 over 2 consecutive weeks during Screening
The Patient Global Impression of Change (Cataplexy) is a participant-reported outcome used to evaluate the effectiveness of a treatment on their cataplexy symptoms.
Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)
Change in severity of fatigue as measured by the Patient Global Impression of Severity (Fatigue)
The Patient Global Impression of Severity (Fatigue) is a participant-reported assessment that gauges the severity of a participant's fatigue symptoms.
Time frame: Baseline to the end of Double-blind Treatment Period (8 weeks)
Change in severity of fatigue as measured by the Patient Global Impression of Change (Fatigue)
The Patient Global Impression of Change (Fatigue) is a participant-reported outcome used to evaluate the effectiveness of a treatment on their fatigue symptoms.
Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)
Change in severity of narcolepsy symptoms as measured by the Narcolepsy Severity Scale (for participants with NT1) or Narcolepsy Severity Scale-2 (for participants with NT2)
The Narcolepsy Severity Scale is a 15-item participant-reported questionnaire that assesses the severity and consequences of narcolepsy symptoms.
Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)
Change in cognitive complaints as measured by the British Columbia Cognitive Complaints Inventory
The British Columbia Cognitive Complaints Inventory is a participant-reported, 6-item, 4-point scale that assesses perceived cognitive difficulties.
Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)
Change in health-related quality of life as measured by the Short Form-36 physical and mental component summaries
The Short Form-36 includes 36 questions across 8 health domains to measure a participant's functional health and well-being.
Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)
Change in work productivity as measured by the Work Productivity and Activity Impairment: Narcolepsy work productivity loss score
The Work Productivity and Activity Impairment: Narcolepsy questionnaire is a 6-item scale used to measure impairments over 7 days.
Time frame: Baseline to the end of the Double-blind Treatment Period (8 weeks)
Incidence of treatment-emergent adverse events
A treatment-emergent adverse event is any adverse event reported after the first dose of study drug and up to 30 days after final dose of study drug, or any worsening of a pre-existing condition reported after first dose of study drug and up to 30 days after final dose of study drug.
Time frame: Throughout study (16 months, including Open-label Extension)
Evaluate the pharmacokinetic concentrations of pitolisant and major identified metabolites
Pharmacokinetics is the study of how the body interacts with administered substances for the duration of exposure.
Time frame: Throughout study (16 weeks)
Not enrolling at this site — choose another above.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Oct 2027, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HBS-301
Harmony Biosciences Management, Inc. →